PALLiON - PALLiative Care In ONcology
NCT03088202 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 659
Last updated 2023-03-24
Summary
A major concern in today's oncology is the complexity of treatment that increases costs. A main contributor is the increasing use of chemo- and radiotherapy during end of life (EoL: the last 12 months of life). Importantly, intensive chemotherapy in EoL has uncertain efficacy, may result in frequent hospitalizations and less time spent at home. Also, patients with incurable disease who receive intensive treatment at EoL have worse quality of life (QoL). A systematic palliative care (PC) approach that focuses on optimal symptom management and maintenance of QoL of patients and family is often introduced too late in the disease trajectory. Studies indicate that early introduction of PC in patients with unfavorable prognosis may improve QoL and other symptoms and prolong survival. These and related findings have made international stakeholders advocate a stronger integration of oncology and PC for patients with incurable cancer.
The present project is a national multicenter cluster-randomized trial (RCT) in 12 oncology departments in all 4 Norwegian health regions. The project tests the efficacy of a complex tripod intervention that integrates oncology and PC for cancer patients with a life-expectancy \<12 months who receive chemotherapy and includes: A) systematic electronic assessment of symptoms, B) implementation of standardized care pathways and C) an education program for oncologists/PC physicians. The PC pathway focuses on the patient's journey through the PC trajectory including EoL care in order to improve quality of care and reduce the variability in clinical practice and costs. The intervention aims at empowering physicians, patients and relatives and promoting shared-decision-making.
Conditions
- Neoplasia Prostate
Interventions
- OTHER
-
Educational program
E-learning lectures, group exercises, skills training
- OTHER
-
Standardized care pathways
Pathways for systematic follow-up
- OTHER
-
Early palliative care
Compulsory referral to palliative care at inclusion
Sponsors & Collaborators
-
Norwegian University of Science and Technology
collaborator OTHER -
Oslo University Hospital
lead OTHER
Principal Investigators
-
Jon H Loge, PhD · Professor
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-03-22
- Primary Completion
- 2022-12-31
- Completion
- 2022-12-31
Countries
- Norway
Study Locations
More Related Trials
-
State of the Art Photon Therapy Versus Particle Therapy for Small Lung Tumors; a Planning Study Based on a Reference Dataset of Patients
NCT02038413 ·Status: COMPLETED
-
Standard of Care Lifestyle Support for Stage III NSCLC Patients
NCT05287971 ·Status: WITHDRAWN
-
Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
NCT03087708 ·Status: TERMINATED ·Phase: PHASE2
-
Hypoxia-guided Radiotherapy With Cisplatin-etoposide in Stage I-III : Small Cell Lung Cancer(SCLC)
NCT01210131 ·Status: WITHDRAWN ·Phase: NA
-
MPDL3280A With Chemoradiation for Lung Cancer
NCT02525757 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
NCT00495170 ·Status: COMPLETED ·Phase: PHASE2
-
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT01486602 ·Status: COMPLETED ·Phase: PHASE1
-
Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)
NCT00102804 ·Status: COMPLETED ·Phase: PHASE3
-
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer
NCT03774732 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer
NCT02157116 ·Status: TERMINATED ·Phase: PHASE2
-
Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim
NCT00280787 ·Status: COMPLETED ·Phase: PHASE2
-
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
NCT00932893 ·Status: COMPLETED ·Phase: PHASE3
-
Single Arm on the Tolerability of Weekly Nab-paclitaxel
NCT01702844 ·Status: COMPLETED ·Phase: PHASE2
-
Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC
NCT01562210 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer
NCT01770418 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)
NCT00174772 ·Status: COMPLETED ·Phase: PHASE2
-
Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor
NCT02069158 ·Status: COMPLETED ·Phase: PHASE1
-
FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer
NCT00020202 ·Status: COMPLETED ·Phase: PHASE2
-
Carboplatin and Paclitaxel in Treating Older Patients With Metastatic or Recurrent Unresectable Non-small Cell Lung Cancer
NCT00005059 ·Status: COMPLETED ·Phase: PHASE2
-
Paclitaxel, Carboplatin, and Radiation Therapy With or Without Adjuvant Paclitaxel and Carboplatin in Treating Patients With Stage II or Stage III Unresectable Non-Small Cell Lung Cancer
NCT00077220 ·Status: UNKNOWN ·Phase: PHASE3
-
PBF-1129 in Patients With NSCLC
NCT03274479 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
NCT01441128 ·Status: TERMINATED ·Phase: PHASE1
-
Palliative Thoracic Radiotherapy Plus BKM120
NCT02128724 ·Status: COMPLETED ·Phase: PHASE1
-
An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT01711697 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
NCT02122146 ·Status: TERMINATED ·Phase: PHASE1